Welcome to our dedicated page for Dentsply Sirona news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on Dentsply Sirona stock.
DENTSPLY SIRONA Inc. develops, manufactures and markets professional dental products, dental technologies, oral health products and other consumable medical devices under a broad brand portfolio. News for XRAY commonly covers quarterly results, outlook updates, restructuring actions, capital allocation, debt reduction, share repurchases and changes to distribution relationships for dental equipment and connected technology solutions.
Company updates also focus on digital dentistry and imaging products, including CEREC systems, intraoral scanning, CBCT imaging, DS Core, Smart View - Detect and dental-dedicated MRI work with Siemens Healthineers. Additional product news includes Surity urinary incontinence devices from Wellspect HealthCare, along with regulatory clearances, CE markings, commercial launches, board changes and investor conference participation.
Wellspect HealthCare (NASDAQ:XRAY) launched the Surity™ Male External Catheter in the U.S. on April 30, 2026, expanding its Surity™ continence portfolio already including a female catheter and an upcoming Surity™ Urinary Management System.
The device is non‑invasive, suitable for up to 24 hours wear, features a see‑through design and slim profile, and is available now for home purchase at www.surity.care; institutional availability is described as coming soon.
Dentsply Sirona (Nasdaq: XRAY) will host a first quarter 2026 results conference call and live webcast on Tuesday, May 5, 2026 at 4:30 p.m. ET. Financial earnings materials and the live webcast link will be posted in the Investors section of the company website prior to the call.
A replay of the webcast will be available on the Investors website after the call.
Dentsply Sirona and Siemens Healthineers (NYSE: XRAY) announced FDA clearance of the MAGNETOM Free.Max Dental Edition, the first dental-dedicated MRI, following a clinical trial validating its use across endodontics, periodontics, TMJ, extraction, and orthodontics.
The trial highlighted non-ionizing imaging, dental-specific field of view, under 20-minute average workflow, soft-tissue contrast that differentiates active inflammation and assesses tooth pulp vitality, and positioning relative to nerves. Training and demonstrations planned April 2026 and at ADEA March 21–24, 2026 in Montréal.
Dentsply Sirona (Nasdaq: XRAY) will present at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 10:00 a.m. EST.
Investors can listen via a live audio webcast and access a replay through the Investors section of the company's website at https://investor.dentsplysirona.com.
Dentsply Sirona (Nasdaq: XRAY) reported Q4 2025 net sales of $961M (+6.2% vs. Q4 2024; constant currency +2.5%) and Q4 adjusted EPS of $0.27. GAAP results included $144M goodwill and intangible impairments, producing a Q4 net loss of ($146M) and diluted loss per share of ($0.74).
Full‑year 2025 net sales were $3.68B (down 3.0%); FY adjusted EPS was $1.60. The company announced a restructuring with ~$55–65M charges, ~$120M annualized savings, elimination of the quarterly dividend, and FY 2026 guidance of $3.5B–$3.6B sales and adjusted EPS $1.40–$1.50.
Dentsply Sirona (Nasdaq: XRAY) announced the appointments of James D. Forbes and Brian P. McKeon to its Board of Directors, effective February 27, 2026. Forbes brings 30 years of healthcare investment banking experience and will join the Compensation & Human Capital Committee. McKeon brings 25 years of CFO experience and will join the Audit and Finance Committee and Science and Technology Committee. The appointments aim to strengthen strategic, financial and governance capabilities to support the company’s Return-to-Growth action plan. In connection with board refreshment, Willie Deese intends to retire and will not stand for re-election after 15 years of service.
Dentsply Sirona (NASDAQ:XRAY) and Burkhart Dental Supply expanded their distribution partnership effective April 1, 2026, with Burkhart adding Dentsply Sirona’s full dental technology portfolio to its existing preventive and restorative offerings.
This includes CEREC systems, Primescan and Primescan 2 scanners, Axeos and Orthophos imaging, and aims to simplify purchasing and local support for dental practices.
Dentsply Sirona (Nasdaq: XRAY) will host a conference call and live webcast on Thursday, February 26, 2026 at 4:30 p.m. EST to review fourth quarter and full year 2025 financial results. A press release and a presentation with summary financial information will be posted on the company’s Investors website prior to the call.
The live webcast and a replay will be available at https://investor.dentsplysirona.com, and registered participants may join the call via the provided registration link.
Wellspect HealthCare (XRAY) announced the U.S. launch of the Surity™ Female External Catheter, a non-invasive product intended to help women with severe urinary incontinence and their caregivers. The device is designed to prevent leakage, protect skin, and support extended overnight use while integrating with compatible urine collection systems.
The company said Surity™ addresses a gap in continence care for aging, neurologic, and mobility-limited populations. The female catheter is available for home purchase at www.surity.care, and a Surity™ urinary management system plus a male external catheter are planned for launch later in the year.
Dentsply Sirona (Nasdaq: XRAY) and Patterson Dental announced on January 14, 2026 the renewal of their U.S. dental technology distribution agreement. The partnership continues long‑standing distribution of Dentsply Sirona’s technology portfolio—including CEREC, Primescan, Axeos and Orthophos—to Patterson Dental customers, supported by service and support. The companies say the renewal aims to accelerate adoption of integrated, connected dentistry solutions that link devices, software and services to improve practice efficiency and patient care.
The agreement emphasizes continued access to Dentsply Sirona products through Patterson Dental and a joint focus on growth and innovation in dental technology distribution in the U.S.